Similar articles for PMID: 21812020

Year	Number of Results
1997	1
2002	2
2003	1
2004	3
2005	1
2006	2
2007	1
2008	3
2009	12
2010	16
2011	18
2012	35
2013	31
2014	15
2015	7
2016	4
2017	5
2018	4
2019	1
2020	1
2022	1
2024	0

1

Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.

Smock KJ, Saunders PJ, Rodgers GM, Johari V. Smock KJ, et al. Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Epub 2011 Aug 2. Am J Hematol. 2011. PMID: 21812020 Free article. Review.

2

Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.

Sardella G, Calcagno S, Mancone M, Palmirotta R, Lucisano L, Canali E, Stio RE, Pennacchi M, Di Roma A, Benedetti G, Guadagni F, Biondi-Zoccai G, Fedele F. Sardella G, et al. Circ Cardiovasc Interv. 2012 Oct;5(5):698-704. doi: 10.1161/CIRCINTERVENTIONS.112.972463. Epub 2012 Oct 9. Circ Cardiovasc Interv. 2012. PMID: 23048056 Clinical Trial.

3

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ. Brandt JT, et al. J Thromb Haemost. 2007 Dec;5(12):2429-36. doi: 10.1111/j.1538-7836.2007.02775.x. Epub 2007 Sep 26. J Thromb Haemost. 2007. PMID: 17900275 Free article.

4

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA. Price MJ, et al. Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Rev Cardiovasc Med. 2011. PMID: 21546883 Review.

5

The P2Y12 receptor: no active metabolite, no party.

Patrono C. Patrono C. Nat Rev Cardiol. 2009 Apr;6(4):271-2. doi: 10.1038/nrcardio.2009.29. Nat Rev Cardiol. 2009. PMID: 19352330

6

The impact of genetic polymorphisms of P2Y12, CYP3A5 and CYP2C19 on clopidogrel response variability in Iranian patients.

Namazi S, Kojuri J, Khalili A, Azarpira N. Namazi S, et al. Biochem Pharmacol. 2012 Apr 1;83(7):903-8. doi: 10.1016/j.bcp.2012.01.003. Epub 2012 Jan 12. Biochem Pharmacol. 2012. PMID: 22265638 Clinical Trial.

7

Response variability to clopidogrel: is tailored treatment, based on laboratory testing, the right solution?

Cattaneo M. Cattaneo M. J Thromb Haemost. 2012 Mar;10(3):327-36. doi: 10.1111/j.1538-7836.2011.04602.x. J Thromb Haemost. 2012. PMID: 22221409 Free article. Review.

8

High on-treatment platelet reactivity and P2Y12 antagonists in clinical trials.

Trenk D, Kristensen SD, Hochholzer W, Neumann FJ. Trenk D, et al. Thromb Haemost. 2013 May;109(5):834-45. doi: 10.1160/TH12-08-0588. Epub 2012 Dec 13. Thromb Haemost. 2013. PMID: 23238773 Review.

9

The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.

Bernlochner I, Byrne RA, Kastrati A, Sibbing D. Bernlochner I, et al. Expert Rev Cardiovasc Ther. 2011 Aug;9(8):999-1014. doi: 10.1586/erc.11.80. Expert Rev Cardiovasc Ther. 2011. PMID: 21878045 Review.

10

Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study.

Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Siller-Matula JM, et al. J Thromb Haemost. 2012 Apr;10(4):529-42. doi: 10.1111/j.1538-7836.2012.04639.x. J Thromb Haemost. 2012. PMID: 22260716 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

145 results

Results by year